These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29860890)

  • 1. Bicalutamide enhances fodrin-mediated apoptosis through calpain in LNCaP.
    Lee J; Mun S; Park A; Kim D; Heun Cha B; Kang HG
    Exp Biol Med (Maywood); 2018 Jun; 243(10):843-851. PubMed ID: 29860890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
    Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.
    Floyd MS; Teahan SJ; Fitzpatrick JM; Watson RW
    Prostate Cancer Prostatic Dis; 2009; 12(1):25-33. PubMed ID: 18475288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
    Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
    Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.
    Wang T; Alavian MR; Goel HL; Languino LR; Fitzgerald TJ
    Prostate; 2008 Dec; 68(16):1734-42. PubMed ID: 18729104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
    Bennett HL; Stockley J; Fleming JT; Mandal R; O'Prey J; Ryan KM; Robson CN; Leung HY
    BJU Int; 2013 Apr; 111(4):672-82. PubMed ID: 22897391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
    Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
    Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.
    Bühler P; Fischer T; Wolf P; Gierschner D; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U
    Urol Int; 2010; 84(2):203-11. PubMed ID: 20215827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC; Astapova I; Hollenberg AN; Balk SP
    Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
    Salman H; Bergman M; Blumberger N; Djaldetti M; Bessler H
    Biomed Pharmacother; 2014 Feb; 68(1):21-4. PubMed ID: 24406295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide.
    Stanisławska IJ; Piwowarski JP; Granica S; Kiss AK
    Phytomedicine; 2018 Jul; 46():176-183. PubMed ID: 30097116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
    Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micellar delivery of bicalutamide and embelin for treating prostate cancer.
    Danquah M; Li F; Duke CB; Miller DD; Mahato RI
    Pharm Res; 2009 Sep; 26(9):2081-92. PubMed ID: 19415464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
    Colabufo NA; Pagliarulo V; Berardi F; Contino M; Inglese C; Niso M; Ancona P; Albo G; Pagliarulo A; Perrone R
    Eur J Pharmacol; 2008 Dec; 601(1-3):38-42. PubMed ID: 18992739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.